Association between Bax degradation activity, prognostic markers, and clinical outcome
| Case no. . | Bax degradation activity . | Binet stage . | IgVH mutation, % . | ZAP-70 . | CD38 . | LDT, mo . | Karyotype* . | Treatment, mo from diagnosis . | Survival, mo from diagnosis . |
|---|---|---|---|---|---|---|---|---|---|
| CLL-1 | Pos | A | 0 | + | + | 10 | (D13S319x1) | Y, 12 | alive, 63 |
| CLL-2 | Pos | B | 0 | + | + | N/A | (ATMx1), (D13S319x1) | Y, 2 | alive, 81 |
| CLL-3 | Pos | C | 0 | + | + | N/A | na | Y, 1 | dead, 30 |
| CLL-4 | Pos | A | 3.6 | − | − | >12 | (D13S319x1) | Y, 36 | alive, 39 |
| CLL-5 | Pos | A | na | − | − | >12 | (D13S319x1) | N, N/A | alive, 135 |
| CLL-6 | Pos | A | 0 | + | − | N/A | (D13S319x1), (p53x1) | Y, 2 | dead, 126 |
| CLL-7 | Pos | A | 1 | + | − | 6 | (D13S319x1) | N, N/A | dead, 36 |
| CLL-8 | Pos | C | 1.7 | − | − | N/A | +12, +19 | Y, 1 | dead, 210 |
| CLL-9 | Pos | B | 3.6 | + | + | 6 | Normal | Y, 10 | alive, 33 |
| CLL-10 | Pos | A | 7.6 | + | + | 4 | (D13S319x1)/(D13S319x0) (CEP12x3) | N, N/A | alive, 63 |
| CLL-11 | Pos | A | na | + | − | >12 | del(11)(q22q23) | Y, 39 | alive, 69 |
| CLL-12 | Pos | B | 2.9 | + | + | 7 | Complex† | Y, 1 | dead, 18 |
| CLL-13 | Pos | A | 12.5 | − | + | >12 | (D13S319x1)/(D13S319x0) | Y, 108 | alive, 123 |
| CLL-14 | Pos | A | 0 | + | + | >12 | (ATMx1) | Y, 54 | dead, 84 |
| CLL-15 | Pos | A | 0.7 | + | + | >12 | (D13S319x1)/(D13S319x0) | N, N/A | alive, 60 |
| CLL-16 | Pos | B | na | − | + | N/A | Complex‡ | Y, 0.25 | dead, 10 |
| CLL-17 | Pos | A | 8.7 | − | + | >12 | (D13S319x1)/(D13S319x0) (CEP12x3) | Y, 72 | alive, 111 |
| CLL-18 | Pos | B | 0 | + | + | 6 | Normal | Y, 12 | dead, 144 |
| CLL-19 | Pos | A | na | − | − | >12 | (D13S319x1)/(D13S319x0) (p53x1) | NN/A | alive, 41 |
| CLL-20 | Pos | C | na | − | + | >12 | Normal | Y, 9 | dead, 31 |
| CLL-21 | Pos | A | na | − | − | >12 | Normal | N, N/A | alive, 12 |
| CLL-22 | Pos | A | 5.7 | − | + | N/A | (D13S319x1) | Y, 4 | alive, 75 |
| CLL-23 | Pos | B | 4.0 | − | − | 7 | (D13S319x0) | Y, 12 | alive, 15 |
| CLL-34 | Pos | B | 6.0 | − | − | N/A | (D13S319x1)/(D13S319x0) (CEP12x3)/(IGHsp) | Y, 1 | alive, 11 |
| CLL-37 | Pos | A | 9.4 | − | − | >12 | (D13S319x1) | Y, 36 | alive, 43 |
| CLL-38 | Pos | A | 8.0 | − | + | 6 | (D13S319x1)/(D13S319x0) | N, N/A | alive, 27 |
| CLL-24 | Neg | A | 10 | − | − | >12 | (D13S319x1)/(D13S319x0) | N, N/A | alive, 75 |
| CLL-25 | Neg | A | 0 | + | + | N/A | (CEP12x3) | Y, 4 | dead, 144 |
| CLL-26 | Neg | A | 15.9 | − | − | >12 | Normal | Y, 180 | alive, 195 |
| CLL-27 | Neg | A | 8.8 | − | − | >12 | (D13S319x1) | N, N/A | alive, 63 |
| CLL-28 | Neg | A | na | − | − | >12 | (D13S319x0) | N, N/A | alive, 135 |
| CLL-29 | Neg | A | 7.4 | − | − | >12 | (D13S319x1)/(D13S319x0) | Y, 156 | alive, 171 |
| CLL-30 | Neg | A | na | na | + | >12 | t(6;13)(p21;q14),add(14)(q32)/ (D13S319x1) | Y, 90 | alive, 123 |
| CLL-31 | Neg | A | na | − | − | >12 | (D13S319x1)/(D13S319x0) | N, N/A | alive, 123 |
| CLL-32 | Neg | A | na | − | − | 3 | (D13S319x1)/(D13S319x0) | Y, 2 | alive, 147 |
| CLL-33 | Neg | A | 1.2 | − | − | >12 | (D13S319x1)/(D13S319x0) | N, N/A | alive, 123 |
| CLL-35 | Neg | B | 0 | + | + | 10 | Normal | N, N/A | alive, 15 |
| CLL-36 | Neg | A | 1.0 | + | − | > 12 | +12,del(14)(q13q32)/(CEP12x3) | Y, 25 | alive, 66 |
| CLL-39 | Neg | A | na | − | − | >12 | Normal | N, N/A | alive, 70 |
| CLL-40 | Neg | A | 5.0 | − | − | 9 | (D13S319x1) | Y, 34 | alive, 45 |
| Case no. . | Bax degradation activity . | Binet stage . | IgVH mutation, % . | ZAP-70 . | CD38 . | LDT, mo . | Karyotype* . | Treatment, mo from diagnosis . | Survival, mo from diagnosis . |
|---|---|---|---|---|---|---|---|---|---|
| CLL-1 | Pos | A | 0 | + | + | 10 | (D13S319x1) | Y, 12 | alive, 63 |
| CLL-2 | Pos | B | 0 | + | + | N/A | (ATMx1), (D13S319x1) | Y, 2 | alive, 81 |
| CLL-3 | Pos | C | 0 | + | + | N/A | na | Y, 1 | dead, 30 |
| CLL-4 | Pos | A | 3.6 | − | − | >12 | (D13S319x1) | Y, 36 | alive, 39 |
| CLL-5 | Pos | A | na | − | − | >12 | (D13S319x1) | N, N/A | alive, 135 |
| CLL-6 | Pos | A | 0 | + | − | N/A | (D13S319x1), (p53x1) | Y, 2 | dead, 126 |
| CLL-7 | Pos | A | 1 | + | − | 6 | (D13S319x1) | N, N/A | dead, 36 |
| CLL-8 | Pos | C | 1.7 | − | − | N/A | +12, +19 | Y, 1 | dead, 210 |
| CLL-9 | Pos | B | 3.6 | + | + | 6 | Normal | Y, 10 | alive, 33 |
| CLL-10 | Pos | A | 7.6 | + | + | 4 | (D13S319x1)/(D13S319x0) (CEP12x3) | N, N/A | alive, 63 |
| CLL-11 | Pos | A | na | + | − | >12 | del(11)(q22q23) | Y, 39 | alive, 69 |
| CLL-12 | Pos | B | 2.9 | + | + | 7 | Complex† | Y, 1 | dead, 18 |
| CLL-13 | Pos | A | 12.5 | − | + | >12 | (D13S319x1)/(D13S319x0) | Y, 108 | alive, 123 |
| CLL-14 | Pos | A | 0 | + | + | >12 | (ATMx1) | Y, 54 | dead, 84 |
| CLL-15 | Pos | A | 0.7 | + | + | >12 | (D13S319x1)/(D13S319x0) | N, N/A | alive, 60 |
| CLL-16 | Pos | B | na | − | + | N/A | Complex‡ | Y, 0.25 | dead, 10 |
| CLL-17 | Pos | A | 8.7 | − | + | >12 | (D13S319x1)/(D13S319x0) (CEP12x3) | Y, 72 | alive, 111 |
| CLL-18 | Pos | B | 0 | + | + | 6 | Normal | Y, 12 | dead, 144 |
| CLL-19 | Pos | A | na | − | − | >12 | (D13S319x1)/(D13S319x0) (p53x1) | NN/A | alive, 41 |
| CLL-20 | Pos | C | na | − | + | >12 | Normal | Y, 9 | dead, 31 |
| CLL-21 | Pos | A | na | − | − | >12 | Normal | N, N/A | alive, 12 |
| CLL-22 | Pos | A | 5.7 | − | + | N/A | (D13S319x1) | Y, 4 | alive, 75 |
| CLL-23 | Pos | B | 4.0 | − | − | 7 | (D13S319x0) | Y, 12 | alive, 15 |
| CLL-34 | Pos | B | 6.0 | − | − | N/A | (D13S319x1)/(D13S319x0) (CEP12x3)/(IGHsp) | Y, 1 | alive, 11 |
| CLL-37 | Pos | A | 9.4 | − | − | >12 | (D13S319x1) | Y, 36 | alive, 43 |
| CLL-38 | Pos | A | 8.0 | − | + | 6 | (D13S319x1)/(D13S319x0) | N, N/A | alive, 27 |
| CLL-24 | Neg | A | 10 | − | − | >12 | (D13S319x1)/(D13S319x0) | N, N/A | alive, 75 |
| CLL-25 | Neg | A | 0 | + | + | N/A | (CEP12x3) | Y, 4 | dead, 144 |
| CLL-26 | Neg | A | 15.9 | − | − | >12 | Normal | Y, 180 | alive, 195 |
| CLL-27 | Neg | A | 8.8 | − | − | >12 | (D13S319x1) | N, N/A | alive, 63 |
| CLL-28 | Neg | A | na | − | − | >12 | (D13S319x0) | N, N/A | alive, 135 |
| CLL-29 | Neg | A | 7.4 | − | − | >12 | (D13S319x1)/(D13S319x0) | Y, 156 | alive, 171 |
| CLL-30 | Neg | A | na | na | + | >12 | t(6;13)(p21;q14),add(14)(q32)/ (D13S319x1) | Y, 90 | alive, 123 |
| CLL-31 | Neg | A | na | − | − | >12 | (D13S319x1)/(D13S319x0) | N, N/A | alive, 123 |
| CLL-32 | Neg | A | na | − | − | 3 | (D13S319x1)/(D13S319x0) | Y, 2 | alive, 147 |
| CLL-33 | Neg | A | 1.2 | − | − | >12 | (D13S319x1)/(D13S319x0) | N, N/A | alive, 123 |
| CLL-35 | Neg | B | 0 | + | + | 10 | Normal | N, N/A | alive, 15 |
| CLL-36 | Neg | A | 1.0 | + | − | > 12 | +12,del(14)(q13q32)/(CEP12x3) | Y, 25 | alive, 66 |
| CLL-39 | Neg | A | na | − | − | >12 | Normal | N, N/A | alive, 70 |
| CLL-40 | Neg | A | 5.0 | − | − | 9 | (D13S319x1) | Y, 34 | alive, 45 |
The Binet stage was the clinical stage at diagnosis. IgVH used less than 2% as the threshold for unmutated vs mutated.
LDT indicates lymphocyte doubling time; na, not available; N/A, not applicable (treatment started before LDT assessable); N, no; Y, yes; Pos or +, positive; Neg or −, negative; unmut, unmutated; mut, mutated; x1, monoallelic deletion; x0, biallelic deletion; Normal, all FISH probes were present in 2 copies; and Complex, more than 3 cytogenetic abnormalities.
D13S319 was the probe for 13q14; ATM, for 11q22; CEP12, for chromosome 12 enumeration; IGH [,] for 14q32; p53, for 17p13.
Complex includes loss of 9p, partial trisomy 12q, loss of 17p.
Complex includes del (13) (q1q2) and 14q32 rearrangement.